Comparing Human Pheromone Sciences (OTCMKTS:EROX) and Oddity Tech (NASDAQ:ODD)

Human Pheromone Sciences (OTCMKTS:EROXGet Free Report) and Oddity Tech (NASDAQ:ODDGet Free Report) are both consumer staples companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, institutional ownership, analyst recommendations and profitability.

Earnings and Valuation

This table compares Human Pheromone Sciences and Oddity Tech’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Human Pheromone Sciences N/A N/A N/A N/A N/A
Oddity Tech $508.68 million 4.39 $58.53 million $1.20 32.72

Oddity Tech has higher revenue and earnings than Human Pheromone Sciences.

Insider & Institutional Ownership

35.9% of Oddity Tech shares are owned by institutional investors. 20.7% of Human Pheromone Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Human Pheromone Sciences and Oddity Tech’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Human Pheromone Sciences N/A N/A N/A
Oddity Tech 12.97% 26.10% 17.35%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Human Pheromone Sciences and Oddity Tech, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Human Pheromone Sciences 0 0 0 0 N/A
Oddity Tech 0 3 5 0 2.63

Oddity Tech has a consensus target price of $53.75, indicating a potential upside of 36.91%. Given Oddity Tech’s higher probable upside, analysts clearly believe Oddity Tech is more favorable than Human Pheromone Sciences.

Summary

Oddity Tech beats Human Pheromone Sciences on 7 of the 8 factors compared between the two stocks.

About Human Pheromone Sciences

(Get Free Report)

Human Pheromone Sciences, Inc. engages in the research, development, manufacture, and marketing of consumer products containing synthetic human pheromones and other mood enhancing compounds in the United States and internationally. It provides a line of fragrance and toiletry products for men and women under the Natural Attraction trademark. The company also licenses its initial compounds and related technology, as well as sells its patented compounds to licensed customers to include these compounds as components in their products. In addition, it offers private label manufacturing services to licensed customers. Human Pheromone Sciences, Inc. distributes its products through distributors, as well as through the Web site, naturalattraction.com. The company was formerly known as EROX Corporation and changed its name to Human Pheromone Sciences, Inc. in May 1998. Human Pheromone Sciences, Inc. was founded in 1989 and is headquartered in San Jose, California.

About Oddity Tech

(Get Free Report)

Oddity Tech Ltd. operates as a consumer tech company that builds digital-first brands for the beauty and wellness industries in the United States and internationally. It serves consumers worldwide through its AI-driven online platform, which uses data science, machine learning, and computer vision capabilities to identify consumer needs, and develop solutions in the form of beauty and wellness products. The company sells beauty, hair, and skin products under the IL MAKIAGE and SpoiledChild brands. In addition, it operates ODDITY LABS, a biotechnology center, which develops various ingredients, including novel molecules, probiotics, and peptides for beauty and wellness products. Oddity Tech Ltd. was incorporated in 2013 and is headquartered in Tel Aviv, Israel.

Receive News & Ratings for Human Pheromone Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Human Pheromone Sciences and related companies with MarketBeat.com's FREE daily email newsletter.